Stem Cell Clinic

SpaceX Dragon to launch heart cell experiment and more to space station tonight – Space.com

CAPE CANAVERAL, Fla. SpaceX is preparing for its fifth launch of the year: a resupply mission to the International Space Station (ISS). The mission, which is scheduled to launch Friday (March 6) at 11:50 p.m. EST (0450 GMT on March 7), will bring a bevy of science material to the astronauts living and working in the orbiting laboratory.

This flight, dubbed CRS-20, marks the 20th and final mission for SpaceX under the company's first commercial cargo resupply services contract with NASA. Perched atop a Falcon 9 rocket will sit a cargo Dragon capsule filled with more than 4,300 lbs. (1,950 kilograms) of supplies, including more than 2,100 lbs. (950 kg) of science equipment.

The scientific cargo will support a host of experiments across Expeditions 62 and 63, focusing on a range of topics, from biological sciences (growing human heart cells in space), to water conservation methods, to particle-foam manufacturing and the addition of a new research platform on the ISS.

You can watch SpaceX's Dragon launch livehere on Space.com, courtesy of SpaceX, beginning at about 11:30 p.m. EST (0430 GMT), courtesy of NASA TV. You can alsowatch the launch directly from SpaceX here, beginning at 11:35 p.m. EST (0435 GMT).

Video: What's flying to the space station on SpaceX's CRS-20 mission?Related: SpaceX Dragon cargo ship launching tonight. How to watch live.

In its never-ending quest to create the best athletic shoe, Adidas has turned its sights to the International Space Station. The sportswear company has developed a performance midsole an additional shoe layer between the insole (next to your feet) and the sole (what touches the ground) that will enhance comfort.

To create its midsole, Adidas uses a process called particle foam molding, in which thousands of small pellets are blasted into a mold so they fuse together. To streamline the process and create the best shoe it can, Adidas is going to try this process in microgravity. The experiment, dubbed Adidas BOOST (Boost Orbital Operations on Spheroid Tessellation), will look at how the particles fuse together in space.

By removing gravity from the process, the team can take a closer look at individual pellet motion and location. The results of this investigation could show that the space station is a good platform for testing out new manufacturing methods and could lead to more-efficient means of packing and cushioning materials.

Related: Adidas launching new sneakers inspired by historic NASA spacesuits

Delta Faucet Co., a manufacturer of shower heads and other bathroom hardware, is launching a payload on CRS-20 that will seek to better understand how water droplets form. The company will use that knowledge to build a better shower head that lines up with Delta's ultimate goal: creating the sensation of increased pressure while using less water.

Conserving water is incredibly important, but one of the biggest drawbacks is that eco-friendly, low-flow shower heads do not perform as well as their less environmentally friendly counterparts. Users complain that the water pressure feels so low it's difficult to rinse off properly, which can result in longer showers and, ultimately, more water usage.

To help mitigate this issue, Delta has created a unique shower head, called the H2Okinetic, that controls the size and the speed of the water droplets with the help of an oscillating chip. That chip creates a better shower experience by breaking up the water flow into bigger droplets and shooting them out faster, giving the illusion of more water.

Related: Showering in space: Astronaut home video shows off 'hygiene corner'

"Water is a precious commodity," Garry Marty, principal engineer at Delta Faucet, said during a prelaunch briefing on Thursday (March 5). "We are trying to create a shower head to keep our customers happy while using less water."

He went on to explain that once the water leaves the pipes, it essentially doesn't have any pressure. What you're feeling are the droplets. With this new shower head, Delta Faucet is able to control the size and speed on each drop, revolutionizing the way a shower device delivers a shower.

"Lower-flow showers aren't really great to be under," Marty said. "But the more we understand, the more we can improve."

Marty added that, someday, humanity will be living on the moon or Mars and will need a way to take a shower. The lessons learned from this research go beyond conserving water and user experience, he said; it has implications for the space industry as well. But for now, the bigger concern is to better understand the fundamentals of water droplet formation.

Heart disease is the No. 1 cause of death in the U.S. A team of researchers from Emory University in Atlanta, led by Chunhui Xu, are sending an experiment up to the space station to explore how effectively stem cells can be turned into heart muscle cells.

The data collected could lead to new therapies and even speed up the development of new drugs that can better treat heart disease.

The microgravity environment found on the space station is known to have a profound effect on cell growth. Through this research, the team aims to understand the impact microgravity has on cardiac precursors (cardiac cells created from stem cells) and how effectively they produce cardiac muscle cells, called cardiomyocytes.

Related: Heart cells beat differently in microgravity, may benefit astronauts

Ground-based research shows that when cells are grown under simulated microgravity conditions, the production rate of cardiomyocytes is greater than if they were grown under the effects of gravity. By sending the experiment to the space station, Xu and her team will be able to determine if their results are accurate.

"Our goal is to help make stem cell-based therapy more readily available," Xu said during the briefing. "If successful, the demand for it will be tremendous, because heart disease is the No. 1 killer in America."

In order to have a successful therapy, Xu said that the team will need to produce a large number of high-quality cardiomyocytes. To do that, the researchers need to first understand the mechanisms behind cell transformation.

Bartolomeo is a new research platform that will be installed on the exterior of the space station. Placed outside the European Columbus module, this science balcony will host as many as 12 research experiments at one time.

Built by Airbus, the platform will enable researchers to conduct more experiments on the station's exterior. During a prelaunch briefing, NASA and Airbus explained that Bartolomeos potential uses include Earth observation, robotics, materials science and astrophysics.

"All of your [research] dreams can come true with Bartolomeo," said Andreas Schuette, program manager of Bartolomeo at Airbus.

And parking spots on the washing machine-sized platform are all-inclusive, which means that researchers can pay one price to launch, install, operate and even return to Earth. By working directly with agencies like NASA, ESA, and SpaceX, Airbus is able to offer a cost-effective means of conducting research on the space station.

The company is also working with the United Nations in an effort to entice those who wouldn't otherwise be able to afford to send payloads into space, Schuette told Space.com. The duo have teamed up with the United Nations Office for Outer Space (UNOOSA) to make that happen. (The agency works to make space more accessible.)

If all goes as scheduled, the Dragon will arrive at the International Space Station on Monday (March 9) at approximately 6 a.m. EDT (1000 GMT). From there, NASA astronauts Jessica Meir and Drew Morgan will use the station's Canadarm2 robotic arm to capture and attach the spacecraft, before beginning the unloading process.

Follow Amy Thompson on Twitter @astrogingersnap. Follow us on Twitter @Spacedotcom or Facebook.

View post:
SpaceX Dragon to launch heart cell experiment and more to space station tonight - Space.com

Mutations of virus do not stymie research –

[Photo/Agencies]

Known mutations of the novel coronavirus have not affected overall progress of drug and vaccine development, and scientists will keep monitoring the virus's evolution and plan research projects accordingly, senior scientists said on Friday.

This week, Chinese scientists announced that they had discovered that the virus had evolved into two major subtypes, and detected 149 mutation points across its genomes. The L subtype, considered more aggressive, is believed to have been more prevalent during the early stages of the outbreak in Wuhan, Hubei province, than its S subtype ancestor, which is relatively more prevalent now.

Zhou Qi, deputy secretary-general of the Chinese Academy of Sciences, said the virus's mutations require further research, and China is conducting a coordinated research effort to evaluate the virus and develop a vaccine.

"All research is under control," he said. "The mutations that we now know have not affected our drug, antibody or vaccine development. We will keep monitoring the mutations the virus generates and plan related research projects accordingly."

Zheng Zhongwei, director of the Development Center for Medical Science and Technology of the National Health Commission, said China has nine ongoing research projects on vaccine development, and some will hopefully enter clinical trials in April.

The five main types of vaccines that China is working on are an inactivated vaccine, recombinant subunit vaccine, adenoviral vector vaccine, live attenuated vaccine and nucleic acid-based vaccine.

Zheng said he had not seen reports of foreign researchers working on an inactivated vaccine, which consists of virus particles that no longer have disease-producing capability. As for the recombinant and vector vaccines, he said both have moved into animal trials and their progress is on par with that of other countries.

For drug development, China has expanded the use of trial drugs and treatments, including plasma transfusion, artificial extracorporeal liver support often called liver dialysis and traditional Chinese medicine, said Sun Yanrong, deputy director of the China National Center for Biotechnology Development.

Advanced treatments such as stem cell and monoclonal antibody therapies are also being researched as a way to save patients in critical condition, she added. Chloroquine phosphate has moved from trials to clinical treatment, and no obvious side effects were found in the 285 severely ill patients taking the drug.

Scientists have expanded clinical trials for favipiravir a Japanese antiviral drug that showed promise against the virus in clinical trials in Shenzhen, Guangdong province to cover patients in Wuhan.

Doctors from hospitals in Beijing and Harbin, Heilongjiang province, are doing clinical trials for stem cell therapy and preliminary results have found the treatment safe and effective, Sun said, adding that its use will be expanded in Wuhan.

Clinical results for artificial liver support show it can significantly reduce the treatment time for critically ill patients and improve their recovery rate, she said.

Tocilizumab, a drug that suppresses overreactions of the immune system, has recently been added to the latest treatment and diagnosis guideline of the National Health Commission. It helps to inhibit a deadly medical condition called a cytokine storm an overproduction of immune cells that damages healthy tissues which is also one of the main causes of death for critically ill patients.

Sun said around 272 severely ill patients are being treated with Tocilizumab. The patients came from 14 hospitals in Wuhan, Zhou added. Early clinical data showed that 20 severely or critically ill patients had fevers lowered within a day after receiving the drug, and 19 patients had recovered within two weeks.

Contact the writers at zhangzhihao@chinadaily.com.cn

See original here:
Mutations of virus do not stymie research -

Here’s the Real Reason ‘Hawaii Five-0’ Is Getting Cancelled – Country Living

Hawaii Five-0 has been a TV staple since it debuted in 2010. Weve come to know and love Alex OLoughlins McGarrett and Scott Caan as Danno, and we cant imagine a Friday night without the duo.

But were going to have toand very soon. Hawaii Five-0 has officially been cancelled, and the series finale is slated to air in less than a month.

Its never easy to say goodbye to a hit franchise that carried on the legacy of the original with such distinction, while establishing its own signature style, said Kelly Kahl, President of CBS Entertainment. We cannot be prouder of its quality and longevity and are thankful for the passionate fan devotion it inspired.

But if it had such a passionate viewership, then why would CBS end the series? Heres everything we know.

Besides the fact that its been on 10 whole yearsa pretty lengthy amount of timeit seems there were a few behind-the-scenes factors, too. Deadline claimed Alex and Scotts contracts were up at the end of this season, which often jumpstarts an actors exit.

But the outlet also mentioned that Alex suffered a back injury years ago on set, and that he hasnt quite recovered. He reportedly had a stem cell treatment that helped, but he couldnt sign on for another round. CBS allegedly toyed with the idea of replacing Alex, but instead decided it was time to cut the cord.

The worst news out of all of this is that Hawaii Five-0s final episode will run in less than a month. The two-hour series finale will air on April 3, 2020 so we suggest stocking up on tissues now.

Yes! Apparently James Marsters (Victor Hesse), William Sadler (Jack McGarrett), and Mark Dacascos (Wo Fat) will be back to say goodbye. Theres no word on whether Grace Park or Daniel Dae Kim might return for one last time, but considering their exits seemed a little controversial were not sure we see that happening.

Hopefully they tie everything up as well as Criminal Minds did this year!

Hawaii Five-0

Season 1amazon.com

Hawaii Five-0

Season 3amazon.com

Hawaii Five-0

Season 7amazon.com

Hawaii Five-0

Season 10amazon.com

View original post here:
Here's the Real Reason 'Hawaii Five-0' Is Getting Cancelled - Country Living

Ozzy Osbourne banking on stem cells and pilates to get stage-ready – Calgary Herald

Ozzy Osbourne is banking on stem cell treatment and Pilates to help him manage his Parkinsons disease and get back on stage again.

The Paranoid hitmaker has been laid up since badly injuring himself and suffering from pneumonia last year, revealing he had Parkinsons in January and scrapping his U.S. tour last month, to head to Switzerland for treatment.

In a joint interview with U.K. TV show Good Morning Britain, Ozzy and his wife and manager Sharon opened up about the rockers recovery revealing he is undergoing stem cell treatment to lessen the effects of Parkinsons and boost his immune system.

Theres a professor there (Switzerland), Sharon said. He hasnt got a cure for Parkinsons, no one has but what he can do is he can get Ozzys immune system to here (points high), so now, if Ozzy was to catch a cold it would turn into pneumonia.

This professor has come up with a way of doing stem cells where it helps with the pain. He could hopefully get rid of Ozzys pain and then Ozzy will be healthier to deal with the Parkinsons.

The 71-year-old is not the first person in his family to undergo stem cell treatment, as his son Jack flew to Germany to receive similar therapy to help with his multiple sclerosis.

Meanwhile, the former Black Sabbath frontman has also been working hard to get fit again but thinks he will only truly feel himself again when hes back performing.

I exercise as much as I can. Ive got a trainer, I do Pilates, nurses 24/7, but the best medication I can get is being in front of an audience, which is breaking my heart to be honest, he added. I will (perform again). Absolutely. I will be up there. I have to say that. I know youre going to say what will you do if you cant do it again, thats not an option because I will do it.

More here:
Ozzy Osbourne banking on stem cells and pilates to get stage-ready - Calgary Herald

Stem cell/oxygen-releasing microparticle enhances erectile function in cavernous nerve injury model. – Physician’s Weekly

Erectile dysfunction caused by damage to the cavernous nerve (CN) is a common complication of radical prostatectomy for patients with localized prostate cancer. Various studies have investigated repair of damaged tissue and prevention of fibrosis in the corpus cavernosum using stem cell therapy. However, stem cell therapy has limitations, including insufficient nutrient and oxygen supply to transplanted stem cells. This study investigated whether stem cell/oxygen-releasing hollow microparticles (HP) were therapeutic effect on therapeutic effects on erectile dysfunction in a rat model of bilateral cavernous nerve injury (BCNI). Therapeutic effects were observed in the BCNI model at 1,2, and 4 weeks post-cavernous nerve injury. Erectile function further improved after treatment with stem cell/oxygen-releasing HP system compared treatment with only stem cells at 4 weeks. Stem cell/oxygen-releasing HP system increased cGMP level and nNOS, eNOS, a-SMA and M3 expression, while decreasing fibrosis and apoptosis in the corpus cavernosum. Our results clearly show that stem cell survival increase around transplanted stem cell/oxygen releasing hybrid system site. Taken together, an oxygen-releasing HP system supported prolonged stem cell survival, sustaining the paracrine effect of the stem cells, and consequently enhancing erectile function. These findings show promise with regard to prolonged stem cell survival in stem cell applications for various diseases and types of tissue damage.

Read the original post:
Stem cell/oxygen-releasing microparticle enhances erectile function in cavernous nerve injury model. - Physician's Weekly

South Setauket native announces $100G donation to Stony Brook University Hospital – GreaterMoriches

Ward Melville High Schoolalum Dave Wolmetz was once again surrounded by his heroes.

Last Thursday, Wolmetz who co-owns Urban Air Lake Grove with his partner Keith Handler invited the people that saved his life from Stony Brook University Cancer Center to his family entertainment facility. There, he presented the staff with a check worth $100,000.

Im inspired by the groundbreaking research at the Stony Brook University Cancer Center, said Wolmetz, who began treatment of Acute lymphocytic leukemia (ALL) in 2018 at Stony Brook University Hospital.

The South Setauket native underwent total body radiation and chemotherapy treatment at Stony Brooks Cancer Center and is currently in the management phase of his treatment.

Im grateful for the stem cell transplant and excellent care I have received at the facility, he said. The cancer center is a well-established resource and essential to the community to focus on important cancer problems.

The donation money hails from the Why Not Us Foundation, a nonprofit that is dedicated to creating real and lasting change in the world by motivating, empowering and preparing todays youth to be tomorrows leaders.

The funds will benefit Stony Brooks CAR T-cell therapy program, which supports Stony Brook scientists working on developing personalized cell therapy to treat blood cancers, such as leukemia.

The donation ceremony was timely, as it was the one-year anniversary of Wolmetzs stem cell transplant at Stony Brook.

With the incredible generosity, we will be able to improve cancer care for Long Islanders and generate other CARs directed toward other major blood cancers, such as leukemia and multiple myeloma, said Dr. Huda Salman, a hematologist at Stony Brook. Dave Wolmetz (blue) with members of the Stony Brook University Hospital (courtesy)

Top: Urban Air Lake Grove founders Dave Wolmetz and Keith Handler presenting the $100,000 check to Stony Brook University Hospital.

Follow this link:
South Setauket native announces $100G donation to Stony Brook University Hospital - GreaterMoriches

Cell Therapy Market 2020 Insights on Growth Drivers, Dynamics, Key Players, Investment Analysis, Business Opportunities and Future Trends – 3rd Watch…

The study report on Global Cell Therapy Market delivers the market revenue predictions for each geographical region. In addition, the Cell Therapy report also offers market insight on growth opportunities, disruptive technologies on the basis of innovative business models, several value-added services, and the competitive background of the market which can increase the market growth. Likewise, the report also contains top predictions of the global Cell Therapy market over the forecast period. The report is designed with the forecast period to anticipate the market size of Cell Therapy industry.

Get Sample PDF Report @ https://www.adroitmarketresearch.com/contacts/request-sample/611

The most commonly used process of cell therapy aims to use healthy cells from a donor (Allogeneic) which is compatible or autogenic that is from the patient itself along with their alteration to increase their therapeutic ability. There are various complex steps involved in the process like genetic screening of cell, cell harvesting and reinfusion into the patients body. All these steps are complex and important and have therapeutic result on the patient. These advanced usage of cell therapy will result in growth of the cell therapy market size during the forecast period.

Cell therapy market trends indicate growth owing to the various regulations being approved by the government in the desire to provide quick relief to the patients. Furthermore, many healthcare industries are working in collaboration with the government to identify the various processes to ways to improve cell therapy. Furthermore, the cell therapy market size is also influenced by the commercialization of stem cells treatments.

Browse Complete Report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

The Stem cell therapy segment dominates the types of cell therapy and is said to have the maximum success rate. It has a special feature that it differentiates into any category of cell, at the same time ensuring the individual identity is intact. Industry experts state that the stem cell would revolutionize regenerative medicine, owing to its extensive use in treatment of fatal disease like neurodegenerative, cardiovascular and cancer. The growth of cell therapy market size is also factored to the increased research and development about the same. However, at the same time the huge cost involved in the various processes involved might be hinder the market growth.

The cell therapy market size is segmented on various categories like Clinical-use, Research and Therapy type and region. On the basis of region, North America is projected to contribute the maximum share to the market owing to increased development.

Key players in the market are JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Segmentation:

The various segments of cell therapy market size are:

By Use & Type Outlook

By Cell Therapy Type

By Therapeutic Area

By Therapy Type

By Region

Buy This Report @ https://www.adroitmarketresearch.com/researchreport/purchase/611

About Adroit Market Research:

Adroit Market Research provide quantified B2B research on numerous opportunistic markets, and offer customized research reports, consulting services, and syndicate research reports. We assist our clients to strategize business decisions and attain sustainable growth in their respective domain. Additionally, we support them with their revenue planning, marketing strategies, and assist them to make decisions before the competition so that they remain ahead of the curve.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 (214) 884-6068 / +91 9665341414

Read the original:
Cell Therapy Market 2020 Insights on Growth Drivers, Dynamics, Key Players, Investment Analysis, Business Opportunities and Future Trends - 3rd Watch...

Gilead to Acquire Forty Seven for $4.9 Billion – PharmiWeb.com

Gilead Gains Forty Sevens Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma

Transaction Supports Gileads Strategic Focus in Oncology and Gives Access to Potential New First-in-Class Program and Innovative Pipeline

FOSTER CITY, Calif.&MENLO PARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc.(Nasdaq: GILD) andForty Seven, Inc.(Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for$95.50per share in cash. The transaction, which values Forty Seven at approximately$4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20200302005443/en/

Through the addition of Forty Sevens investigational lead product candidate, magrolimab, the acquisition will strengthen Gileads immuno-oncology research and development portfolio. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). The investigational therapy targets CD47, a do not eat me signal that allows cancer cells to avoid destruction thereby permitting the patients own innate immune system to engulf and eradicate those cancer cells. Forty Seven presented promising results of a Phase 1b study of magrolimab in patients with MDS and AML at theAmerican Society of Hematologymeeting inDecember 2019. Magrolimab has the potential to be a first-in-class therapy.

This agreement builds on Gileads presence in immuno-oncology and adds significant potential to our clinical pipeline, said Daniel ODay, Chairman and Chief Executive Officer ofGilead Sciences. Magrolimab complements our existing work in hematology, adding a non-cell therapy program that complements Kites pipeline of cell therapies for hematological cancers. With a profile that lends itself to combination therapies, magrolimab could potentially have transformative benefits for a range of tumor types. We are looking forward to working with the highly experienced team at Forty Seven to help patients with some of the most challenging forms of cancer.

This is an exciting day for patients who may one day benefit from future anti-CD47 therapies and other immuno-oncology treatments based on our research and an exciting time for Forty Seven as this allows us to achieve our vision of helping patients defeat their cancer, commentedMark McCamish, MD, PhD, President and Chief Executive Officer of Forty Seven. We are pleased to join Gilead and believe that by combining our scientific expertise with Gileads strength in developing treatments that modify the immune system, we will be able to more rapidly advance our therapies.

Magrolimab

Forty Seven is initially studying magrolimab in patients with MDS and AML. Additional studies are ongoing in non-Hodgkin lymphoma (NHL) and solid tumors. Magrolimab has been granted Fast Track designation by theU.S. Food and Drug Administration(FDA) for the treatment of MDS and AML, and for the treatment of relapsed or refractory DLBCL and follicular lymphoma, two forms of B-cell NHL. Magrolimab has also been granted Orphan Drug designation by the FDA for the treatment of MDS and AML and by theEuropean Medicines Agencyfor the treatment of AML.

More than 400 patients have received the compound to date through clinical trials.

Ongoing Phase 1b Clinical Trial

InDecember 2019, Forty Seven presented promising results of a Phase 1b trial evaluating magrolimab in combination with azacitidine in untreated patients with higher risk MDS and untreated patients with AML, who are ineligible for induction chemotherapy. This has led to the initiation of a potential registrational cohort in MDS. All patients received a 1 mg/kg priming dose of magrolimab, coupled with intrapatient dose escalation to mitigate on-target anemia. Patients were then treated with full doses of azacitidine and magrolimab maintenance doses of 30 mg/kg weekly.

As of the data cutoff ofNovember 18, 2019, 62 patients had been treated with the combination in the Phase 1b portion of the trial, including 35 patients with MDS and 27 patients with AML.

Clinical Activity Data

As of the data cutoff, 46 patients were evaluable for response assessment, including 24 patients with untreated higher-risk MDS and 22 patients with untreated AML, who were ineligible for induction chemotherapy.

Safety Data

As of the data cutoff, the combination of magrolimab and azacitidine was well-tolerated, with no evidence of increased toxicities compared to azacitidine alone. Adverse events (AEs) were consistent with prior clinical experience. No deaths were observed in the first 60 days on combination treatment and only one patient out of 62 (1.6 percent) discontinued treatment due to a treatment-related AE.

Additional Programs

Beyond magrolimab, Forty Seven is preparing to advance two additional investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP antibody, is being developed for the treatment of cancer, as well as certain non-oncology settings, including transplantation conditioning.

Terms of the Transaction

Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Forty Sevens common stock at a price of$95.50per share in cash. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer.

Consummation of the tender offer is subject to a minimum tender of at least a majority of outstanding Forty Seven shares plus Forty Seven shares underlying vested options, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

Gilead plans to pay all cash consideration for the transaction. The tender offer is not subject to a financing condition.

Citi and J.P. Morgan are acting as joint financial advisors to Gilead.Centerview Partners LLCis acting as the exclusive financial advisor to Forty Seven.Skadden, Arps, Slate, Meagher & Flom LLPis serving as legal counsel toGileadandCooley LLPis serving as legal counsel to Forty Seven.

Conference Call

At8:00 a.m. Eastern Timetoday, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction. A live webcast of the call can be accessed at Gileads Investors page athttp://investors.gilead.com. Please connect to the website at least 15 minutes prior to the start of the call to allow adequate time for any software download that may be required. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8479332 to access the call.

Telephone replay will be available approximately two hours after the call through8:30 a.m. Eastern Time,March 4, 2020. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 8479332. The webcast will be archived onwww.gilead.comfor one year.

AboutGilead Sciences

Gilead Sciences, Inc.is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters inFoster City, California. For more information onGilead Sciences, please visit the companys website atwww.gilead.com.

About Forty Seven

Forty Seven, Inc.is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed fromStanford University. Forty Sevens lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a dont eat me signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. For more information on Forty Seven, please visit the companys website atwww.fortyseveninc.com.

Original post:
Gilead to Acquire Forty Seven for $4.9 Billion - PharmiWeb.com